Doubling the duration of adjuvant tamoxifen treatment in women estrogen receptor (ER)-positive breast cancer reduces risk of late recurrence and death compared with the current standard-of-care of 5 years' therapy. So say the results of a large international randomized trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium and simultaneously published in The Lancet.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
ADHD linked to higher risk of premenstrual dysphoric disorder
June 26th 2025Women with attention-deficit hyperactivity disorder are over 3 times more likely to experience premenstrual dysphoric disorder, especially when co-occurring with anxiety or depression, according to new research.
Read More